ATE311200T1 - Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten - Google Patents
Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonistenInfo
- Publication number
- ATE311200T1 ATE311200T1 AT01923433T AT01923433T ATE311200T1 AT E311200 T1 ATE311200 T1 AT E311200T1 AT 01923433 T AT01923433 T AT 01923433T AT 01923433 T AT01923433 T AT 01923433T AT E311200 T1 ATE311200 T1 AT E311200T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonists
- compositions
- methods
- allergic conditions
- treating allergic
- Prior art date
Links
- 206010027654 Allergic conditions Diseases 0.000 title abstract 2
- 102000009389 Prostaglandin D receptors Human genes 0.000 title abstract 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19664100P | 2000-04-12 | 2000-04-12 | |
| PCT/CA2001/000491 WO2001078697A2 (en) | 2000-04-12 | 2001-04-09 | Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE311200T1 true ATE311200T1 (de) | 2005-12-15 |
Family
ID=22726224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01923433T ATE311200T1 (de) | 2000-04-12 | 2001-04-09 | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030055077A1 (de) |
| EP (1) | EP1274457B1 (de) |
| JP (1) | JP2003530426A (de) |
| AT (1) | ATE311200T1 (de) |
| AU (1) | AU2001250206A1 (de) |
| CA (1) | CA2405233A1 (de) |
| DE (1) | DE60115411D1 (de) |
| WO (1) | WO2001078697A2 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217725B2 (en) * | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
| US7273883B2 (en) * | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
| WO2004087095A2 (es) * | 2003-03-31 | 2004-10-14 | Osmotica Costa Rica, Sociedad Anonima | Dispositivo osmótico que contiene zafirlukast y un antagonista h1 |
| RU2387652C2 (ru) | 2004-03-11 | 2010-04-27 | Актелион Фармасьютиклз Лтд | Производные тетрагидропиридоиндола |
| TW200716093A (en) * | 2005-04-28 | 2007-05-01 | Shionogi & Co | An antiasthmatic agent containing PGD2 receptor antagonist and leukotriene receptor antagonist |
| KR101289995B1 (ko) | 2005-09-27 | 2013-07-26 | 시오노기 앤드 컴파니, 리미티드 | Ｐｇｄ2 수용체 길항제 활성을 갖는 설폰아마이드 유도체 |
| CN102822163B (zh) | 2009-12-23 | 2016-01-20 | 艾恩伍德医药品股份有限公司 | Crth2调节剂 |
| SG183531A1 (en) | 2010-03-16 | 2012-10-30 | Aventis Pharma Inc | A substituted pyrimidine as a prostaglandin d2 receptor antagonist |
| AU2011227417A1 (en) | 2010-03-16 | 2012-10-11 | Aventis Pharmaceuticals Inc. | Substituted pyrimidines as prostaglandin D2 receptor antagonists |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| WO2011117798A1 (en) | 2010-03-22 | 2011-09-29 | Actelion Pharmaceuticals Ltd | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
| EA026692B1 (ru) | 2010-06-30 | 2017-05-31 | Айронвуд Фармасьютикелз, Инк. | Стимуляторы sgc |
| WO2012009137A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| US20130259830A1 (en) | 2010-07-12 | 2013-10-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2012064559A1 (en) | 2010-11-09 | 2012-05-18 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| MY165623A (en) | 2011-04-14 | 2018-04-18 | Idorsia Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| TW201318624A (zh) | 2011-09-29 | 2013-05-16 | Shionogi & Co | 包含ｐｇｄ２拮抗劑及組織胺拮抗劑之過敏性鼻炎治療用醫藥 |
| EP2797915B1 (de) | 2011-12-27 | 2016-07-13 | Ironwood Pharmaceuticals, Inc. | 2-Benzyl-3-(Oxazol/Thiazol)-5-(Pyrimidin-2-yl)-1(H)-Pyrazol-Derivate als Stimulatoren der löslichen Guanylat-Cyclase (sGC) zur Behandlung von Bluthochdruck und Herzversagen |
| KR101418404B1 (ko) * | 2012-01-06 | 2014-07-10 | 한미약품 주식회사 | 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제 |
| WO2014047111A1 (en) | 2012-09-18 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| CA2885645A1 (en) | 2012-09-19 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| RS63108B1 (sr) | 2013-03-15 | 2022-04-29 | Cyclerion Therapeutics Inc | Sgc stimulatori |
| US20160311826A1 (en) | 2013-12-11 | 2016-10-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| EP3094327A1 (de) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | Verwendung von sgc-stimulatoren zur behandlung von neuromuskulären störungen |
| HRP20181555T1 (hr) | 2014-03-17 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Derivati azaindol-octene kiseline i njihova uporaba kao modulatora receptora prostaglandina d2 |
| RU2016140708A (ru) | 2014-03-18 | 2018-04-18 | Идорсиа Фармасьютиклз Лтд | Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2 |
| US20170298055A1 (en) | 2014-09-17 | 2017-10-19 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| MX2017003518A (es) | 2014-09-17 | 2017-07-28 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
| US20170291889A1 (en) | 2014-09-17 | 2017-10-12 | Ironwood Pharmaceuticals, Inc. | Pyrazole derivatives as sgc stimulators |
| PL3350179T3 (pl) | 2015-09-15 | 2021-08-02 | Idorsia Pharmaceuticals Ltd | Krystaliczne postacie |
| MA45592A (fr) | 2016-07-07 | 2019-05-15 | Ironwood Pharmaceuticals Inc | Promédicaments à base de phosphore de stimulateurs de sgc |
| JP2019524710A (ja) | 2016-07-07 | 2019-09-05 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | Ｓｇｃ刺激剤の固体形態 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565473A (en) * | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| MX9710256A (es) * | 1995-06-21 | 1998-03-31 | Shionogi & Co | Derivados de amino biciclicos y antagonistas pgd2 que contienen los mismos. |
| NZ336143A (en) * | 1996-12-13 | 2002-05-31 | Shionogi & Co | Benzothiophenecarboxamide derivatives and pgd 2 antagonists comprising them |
-
2001
- 2001-04-09 WO PCT/CA2001/000491 patent/WO2001078697A2/en not_active Ceased
- 2001-04-09 EP EP01923433A patent/EP1274457B1/de not_active Expired - Lifetime
- 2001-04-09 JP JP2001575998A patent/JP2003530426A/ja not_active Withdrawn
- 2001-04-09 AU AU2001250206A patent/AU2001250206A1/en not_active Abandoned
- 2001-04-09 AT AT01923433T patent/ATE311200T1/de not_active IP Right Cessation
- 2001-04-09 CA CA002405233A patent/CA2405233A1/en not_active Abandoned
- 2001-04-09 DE DE60115411T patent/DE60115411D1/de not_active Expired - Lifetime
- 2001-04-09 US US10/239,717 patent/US20030055077A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1274457B1 (de) | 2005-11-30 |
| DE60115411D1 (de) | 2006-01-05 |
| JP2003530426A (ja) | 2003-10-14 |
| US20030055077A1 (en) | 2003-03-20 |
| WO2001078697A3 (en) | 2002-08-01 |
| EP1274457A2 (de) | 2003-01-15 |
| CA2405233A1 (en) | 2001-10-25 |
| AU2001250206A1 (en) | 2001-10-30 |
| WO2001078697A2 (en) | 2001-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE311200T1 (de) | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten | |
| ATE293989T1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
| TNSN04001A1 (fr) | Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase. | |
| EP1438054A4 (de) | Verfahren und zusammensetzungen zur behandlung von flaviviren und pestiviren mit 4'-modifiziertem nucleosid | |
| DE60238149D1 (de) | Arylsulfonamid-Derivate zur Verwendung als CCR3-Antagonisten bei der Behandlung von inflammatorischen und immunologischen Erkrankungen | |
| DE60140377D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| DE60039783D1 (de) | Lfa-1 antagonisten und tnf-alpha antagonisten zur | |
| YU97902A (sh) | Ciklopentanoindoli, smeše koje sadrže takva jedinjenja i metodi lečenja | |
| DE60204548D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| DE60135029D1 (de) | Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis | |
| ATE515513T1 (de) | Behandlung von fibrose durch antagonismus zwischen il-13 und il-13-rezeptorketten | |
| ATE406159T1 (de) | Behandlung von hyperlipidämie | |
| DE60212146D1 (de) | Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv | |
| DE60124666D1 (de) | Verfahren zur hydrierung von conjugierten dienpolymeren und copolymeren | |
| ATE496892T1 (de) | Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen | |
| ATE403433T1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
| ATE381938T1 (de) | Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten | |
| ATE371454T1 (de) | Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie | |
| DE60018707D1 (de) | Anti-androgene und verfahren zur behandlung von krankheiten | |
| ATE306272T1 (de) | Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion | |
| DE60314896D1 (de) | 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert | |
| ATE352038T1 (de) | Kit und verfahren zum nachweis von fäkalen parasiten | |
| ATE317268T1 (de) | Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |